drugset / Trial / NCT01010737

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

NCT01010737

Phase 1/2 Completed 60 enrolled BiondVax Pharmaceuticals ltd.
RandomizedParallel-groupSingle-blindPrevention

Summary

This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montanide ISA VG51 Unknown Intramuscular
Subject Multimeric-001 Vaccine 250 ug Intramuscular
Subject Multimeric-001 Vaccine 500 ug Intramuscular
Background Influenza Virus Vaccine Vaccine

Indications